NASDAQ:FONR

FONAR Stock Forecast, Price & News

$17.99
-0.26 (-1.42 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.83
$18.39
50-Day Range
$16.58
$19.00
52-Week Range
$16.58
$26.49
Volume24,426 shs
Average Volume34,393 shs
Market Capitalization$117.91 million
P/E Ratio12.67
Dividend YieldN/A
Beta1
30 days | 90 days | 365 days | Advanced Chart
Receive FONR News and Ratings via Email

Sign-up to receive the latest news and ratings for FONAR and its competitors with MarketBeat's FREE daily newsletter.


About FONAR

FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates through two segments, Medical Equipment segment, and Physician Management and Diagnostic services segment. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters and the development and implementation of practice growth and marketing strategies. The company owns and operates four diagnostic imaging facilities in Florida; and manages 35 MRI scanning facilities, including 22 facilities located in New York and 13 situated in Florida. It markets its scanners to private diagnostic imaging centers and hospitals. The company was founded in 1978 and is based in Melville, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.10 out of 5 stars

Medical Sector

1040th out of 2,099 stocks

Electromedical Equipment Industry

25th out of 62 stocks

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











FONAR (NASDAQ:FONR) Frequently Asked Questions

What stocks does MarketBeat like better than FONAR?

Wall Street analysts have given FONAR a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but FONAR wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting FONAR?

FONAR saw a increase in short interest in the month of May. As of May 14th, there was short interest totaling 212,600 shares, an increase of 22.5% from the April 29th total of 173,500 shares. Based on an average daily volume of 34,700 shares, the short-interest ratio is currently 6.1 days. Approximately 3.4% of the shares of the company are sold short.
View FONAR's Short Interest
.

When is FONAR's next earnings date?

FONAR is scheduled to release its next quarterly earnings announcement on Monday, September 27th 2021.
View our earnings forecast for FONAR
.

How were FONAR's earnings last quarter?

FONAR Co. (NASDAQ:FONR) announced its quarterly earnings results on Friday, May, 14th. The medical equipment provider reported $0.54 EPS for the quarter. The medical equipment provider had revenue of $23.09 million for the quarter. FONAR had a trailing twelve-month return on equity of 7.61% and a net margin of 11.52%.
View FONAR's earnings history
.

How has FONAR's stock been impacted by COVID-19 (Coronavirus)?

FONAR's stock was trading at $15.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, FONR shares have increased by 18.4% and is now trading at $17.99.
View which stocks have been most impacted by COVID-19
.

Who are FONAR's key executives?

FONAR's management team includes the following people:
  • Dr. Raymond V. Damadian, Chairman, Treasurer & Acting Principal Financial Officer (Age 85, Pay $153.1k)
  • Mr. Timothy R. Damadian, CEO & Pres (Age 57)
  • Mr. Luciano B. Bonanni, COO & Exec. VP (Age 66, Pay $146.5k)
  • Ms. Claudette J. V. Chan, Sec. & Director (Age 83, Pay $20k)
  • Mr. Daniel Culver, Director of Communications

Who are some of FONAR's key competitors?

What other stocks do shareholders of FONAR own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FONAR investors own include Gilead Sciences (GILD), Amarin (AMRN), CRISPR Therapeutics (CRSP), Exelixis (EXEL), Pfizer (PFE), Bausch Health Companies (BHC), Incyte (INCY), Jazz Pharmaceuticals (JAZZ), Lannett (LCI) and Madrigal Pharmaceuticals (MDGL).

What is FONAR's stock symbol?

FONAR trades on the NASDAQ under the ticker symbol "FONR."

Who are FONAR's major shareholders?

FONAR's stock is owned by many different retail and institutional investors. Top institutional shareholders include Kayne Anderson Rudnick Investment Management LLC (11.73%), BlackRock Inc. (6.49%), Dimensional Fund Advisors LP (6.09%), LSV Asset Management (3.22%), Brandywine Global Investment Management LLC (1.61%) and Northern Trust Corp (1.49%).
View institutional ownership trends for FONAR
.

Which institutional investors are selling FONAR stock?

FONR stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, LSV Asset Management, Millennium Management LLC, Nuveen Asset Management LLC, Dimensional Fund Advisors LP, Brandywine Global Investment Management LLC, Morgan Stanley, and Kayne Anderson Rudnick Investment Management LLC.
View insider buying and selling activity for FONAR
or view top insider-selling stocks.

Which institutional investors are buying FONAR stock?

FONR stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Assenagon Asset Management S.A., BlackRock Inc., Martingale Asset Management L P, Victory Capital Management Inc., Seizert Capital Partners LLC, Barclays PLC, and Geode Capital Management LLC.
View insider buying and selling activity for FONAR
or or view top insider-buying stocks.

How do I buy shares of FONAR?

Shares of FONR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is FONAR's stock price today?

One share of FONR stock can currently be purchased for approximately $17.99.

How much money does FONAR make?

FONAR has a market capitalization of $117.91 million and generates $85.69 million in revenue each year.

How many employees does FONAR have?

FONAR employs 424 workers across the globe.

What is FONAR's official website?

The official website for FONAR is www.fonar.com.

Where are FONAR's headquarters?

FONAR is headquartered at 110 Marcus Drive, Melville NY, 11747.

How can I contact FONAR?

FONAR's mailing address is 110 Marcus Drive, Melville NY, 11747. The medical equipment provider can be reached via phone at 631-694-2929 or via email at [email protected]


This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.